e-learning
resources
Vienna 2009
Monday, 14.09.2009
Biological and clinical markers in lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC)
R. Zalacain, J. Algorta, N. Marina, A. Gomez, M. Uribarri, B. Calvo, S. Carrera, S. Pedrero, G. Lopez-Vivanco (Baracaldo, Zamudio, Spain)
Source:
Annual Congress 2009 - Biological and clinical markers in lung cancer
Session:
Biological and clinical markers in lung cancer
Session type:
Thematic Poster Session
Number:
2664
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Zalacain, J. Algorta, N. Marina, A. Gomez, M. Uribarri, B. Calvo, S. Carrera, S. Pedrero, G. Lopez-Vivanco (Baracaldo, Zamudio, Spain). Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC). Eur Respir J 2009; 34: Suppl. 53, 2664
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Are there potential characteristical markers in bronquial fluid for diagnosis of small cell lung cancer (SCLC)?
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Small cell lung cancer in patients with elderly
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy
Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease
Year: 2010
Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
New cryobiopsy techniques influence the rate of diagnosis small cell lung cancer (SCLC)
Source: Annual Congress 2010 - The role of endoscopy in the diagnosis of lung cancer
Year: 2010
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002
Staging with FDG-PET/CT influences stage-specific survival in non small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Imaging in oncology and infectious diseases
Year: 2011
Evaluation of serum tumour markers in the lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 268s
Year: 2002
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC)
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019
Extrathoracic 18-FDG-PET uptakes in non small cell lung cancer (NSCLC) preoperative staging
Source: Eur Respir J 2007; 30: Suppl. 51, 430s
Year: 2007
Reflex testing is crucial for treatment decisions in advanced non small cell lung cancer (NSCLC)
Source: International Congress 2017 – Chinese Programme 2017
Year: 2017
Small cell lung cancer patients and their responses to treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 301s
Year: 2004
Tumour infiltrating lymphocytes and tumour associated macrophages in chronic obstructive pulmonary disease (COPD) patients with non-small cell lung cancer (NSCLC) and in patients with NSCLC
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005
Validation and comparison of several published prognostic systems for patients with small cell lung cancer
Source: Eur Respir J 2011; 38: 657-663
Year: 2011
Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s
Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement
Year: 2018
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Characteristics and prognostic relevance of
p
53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept